Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
== R == Rope bridge – Inca rope bridges were suspension bridges made from woven ichu grass, spanning canyons and rivers throughout the Andes. At their peak, at least 200 such bridges connected the Inca road system. Reed boats – a balsa was a boat that was constructed by pre-Columbian South Americans from woven reeds of totora bullrush. These reed boats varied in size from that of a small canoe used for navigation, transportation, and for small-scale fishing to large ships of up to 30 m (98 ft) in length, which were used for war, transportation, bulk goods hauling, and transporting royalty and nobility. They are still used today on Lake Titicaca in Peru and Bolivia by the indigenous peoples living along the banks of the lake. Rubber – the indigenous cultures of Mesoamerica were the first peoples in the world to extract the sap from rubber trees and then use it to make clothes, rubber balls to be played in ceremonial ball games, and many other utilitarian uses. Indigenous peoples, especially those who lived in the Amazon rainforest found many other uses for rubber. The science and technique of extracting sap from rubber trees and then using the sap to make goods made of rubber then spread to the high civilizations of the Andes and elsewhere in the Americas. Rubber balloons – the Olmec were the first people to use rubber balloons. Their civilization arose in 1700 BCE in the Yucatán Peninsula.
=== EC 2.2.1: Transketolases and Transaldolases === EC 2.2.1.1: transketolase EC 2.2.1.2: transaldolase EC 2.2.1.3: formaldehyde transketolase EC 2.2.1.4: acetoin—ribose-5-phosphate transaldolase EC 2.2.1.5: 2-hydroxy-3-oxoadipate synthase EC 2.2.1.6: acetolactate synthase EC 2.2.1.7: 1-deoxy-D-xylulose-5-phosphate synthase EC 2.2.1.8: fluorothreonine transaldolase EC 2.2.1.9: 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase EC 2.2.1.10: 2-amino-3,7-dideoxy-D-threo-hept-6-ulosonate synthase EC 2.2.1.11: 6-deoxy-5-ketofructose 1-phosphate synthase EC 2.2.1.12: 3-acetyloctanal synthase EC 2.2.1.13: apulose-4-phosphate transketolase EC 2.2.1.14: 6-deoxy-6-sulfo-D-fructose transaldolase
=== Jackie Walsh === Jackie Walsh (Caoilfhionn Dunne) is a VP on Pierpoint's FX desk, working alongside Kenny. She is shown to have a kind nature despite her crass sense of humor and seemingly blasé attitude about Pierpoint's work culture. Throughout the first season, she appears to play along with Kenny's workplace bullying, but chastises Yasmin for emulating it in series 2 during Kenny's absence, telling her she is above such behavior. Jackie joins Yasmin and Harper on a trip to Berlin to take over for Yasmin as Anna Gearing's FX contact, after Yasmin announces her departure from FX to private wealth management. Anna takes an immediate liking to Jackie for her acerbic wit. In series 3, Jackie is shown to have left Pierpoint for Goldman Sachs, joining Daria and Kenny in helping Harper short Pierpoint.
Sources: en.wikipedia.org
=== Urea cycle === The urea cycle is a metabolic pathway that results in the formation of urea using one ammonium molecule from degraded amino acids, another ammonium group from aspartate and one bicarbonate molecule. This route commonly occurs in hepatocytes. The reactions related to the urea cycle produce NADH, and NADH can be produced in two different ways. One of these uses oxaloacetate. In the cytosol there are fumarate molecules. Fumarate can be transformed into malate by the actions of the enzyme fumarase. Malate is acted on by malate dehydrogenase to become oxaloacetate, producing a molecule of NADH. After that, oxaloacetate will be recycled to aspartate, as transaminases prefer these keto acids over the others. This recycling maintains the flow of nitrogen into the cell.
The Fifth Avenue station opened in 1926, while the tunnel under Bryant Park to Times Square opened the following year. In January 1927, after the section of the Flushing Line under Bryant Park was complete, plans were announced for a restoration of the park's northern section.
=== Da === Valerie Daggett (BS 1993). American protein chemist at the University of Washington, known for molecular dynamics simulations of proteins and other biomolecules. John Call Dalton (1825–1889). American physiologist at the New York Metropolitan Board of Health, known for detailed and precise sketches of the brain. John W. Daly (1933–2008). American biochemist at the NIH, working primarily on alkaloids. Member Natl. Acad. Sci. USA. Marie Maynard Daly (1921–2003). American biochemist at the Albert Einstein College of Medicine, who studied the chemistry of histones, protein synthesis, the relationships between cholesterol and hypertension, and uptake of creatine by muscle cells. Keith Dalziel FRS (1921–1994). British biochemist at Oxford University, pioneer in analysis of the kinetics of two-substrate enzyme-catalysed reactions. Carl Peter Henrik Dam (1895–1976). Danish biochemist and physiologist at Copenhagen University who discovered vitamin K and its role in human physiology. Nobel Prize in Physiology or Medicine (1943). Marguerite Davis (1887–1967). American biochemist at the University of Wisconsin, co-discoverer of vitamins A and B Ronald W. Davis (b. 1941). American biochemist and geneticist at Stanford, known for developing new technologies in genomics. Member Natl. Acad. Sci. USA. Jean Dausset (1916–2009). French immunologist at INSERM who worked on the major histocompatibility complex. Nobel Prize in Physiology and Medicine (1980). Member Natl. Acad. Sci. USA. Member of the French Academy of Science Margaret Oakley Dayhoff (1925–1983).
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.